Equities analysts forecast that Proteostasis Therapeutics Inc (NASDAQ:PTI) will announce ($0.67) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.72). Proteostasis Therapeutics reported earnings per share of ($0.38) in the same quarter last year, which would indicate a negative year-over-year growth rate of 76.3%. The business is scheduled to announce its next earnings results on Thursday, March 29th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.50) per share for the current fiscal year, with EPS estimates ranging from ($2.56) to ($2.44). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.36) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last announced its earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.
In other news, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $4.88, for a total transaction of $2,459,651.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Meenu Chhabra acquired 40,000 shares of Proteostasis Therapeutics stock in a transaction dated Monday, December 18th. The shares were acquired at an average price of $5.00 per share, with a total value of $200,000.00. Following the transaction, the insider now owns 50,218 shares in the company, valued at approximately $251,090. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 2,100,000 shares of company stock valued at $10,500,000. Insiders own 17.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Jefferies Group LLC bought a new position in shares of Proteostasis Therapeutics during the 4th quarter valued at about $175,000. Jane Street Group LLC bought a new position in shares of Proteostasis Therapeutics during the 4th quarter valued at about $203,000. Goldman Sachs Group Inc. boosted its position in shares of Proteostasis Therapeutics by 364.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock valued at $243,000 after purchasing an additional 40,731 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of Proteostasis Therapeutics during the 2nd quarter valued at about $254,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Proteostasis Therapeutics in the second quarter worth about $296,000. Institutional investors own 55.15% of the company’s stock.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded down $0.21 on Monday, reaching $2.90. 467,172 shares of the company were exchanged, compared to its average volume of 820,666. The company has a market cap of $102.98, a price-to-earnings ratio of -1.31 and a beta of 6.35. Proteostasis Therapeutics has a 12-month low of $1.41 and a 12-month high of $16.67.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/1872882-2/1872882.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.